Krystal Biotech Inc. stocks have been trading up by 5.91 percent following highly positive coverage of its breakthrough gene therapy
Click Here for a Millionaire's POV on Trading KRYS
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Market Insights For KRYS Traders
- BofA raised its price target on Krystal Biotech to $396 from $364 while reiterating a Buy rating, highlighting stronger long-term expectations for Vyjuvek ex-U.S. and increased confidence in KB801.
- Jefferies raised its price target on Krystal Biotech from $399 to $474 and maintained a Buy rating, expecting another strong Q2 on sustained U.S. Vyjuvek demand and rising international revenue.
- TD Cowen raised Krystal Biotech’s price target to $403 from $306 with a Buy rating, pointing to significant expected pipeline value, including de-risked Phase 3 ‘801 NK data and promising early ‘407 cystic fibrosis results.
Weekly Update Jul 13 – Jul 17, 2026: On Saturday, July 18, 2026 Krystal Biotech Inc. stock [NASDAQ: KRYS] is trending up by 5.91%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
Krystal Biotech (KRYS) now operates as a profitable, commercial-stage gene therapy company with exceptional fundamentals relative to small/mid-cap biotech peers. Q1 2026 revenue of $116.4M annualizes well above 2024 levels and supports a 94% gross margin and ~46% operating margin, with free cash flow of ~$73M in the quarter. Balance sheet strength is outstanding: current ratio 9.5, minimal debt (D/E 0.01), and ROE LTM near 20%, albeit at a premium valuation (P/E ~35, P/S ~18.5).
Technically, KRYS is in a strong weekly uptrend, with a sharp rebound from 338 on 7/16 to 362 on 7/17 following a brief pullback from 363.44. The series of higher lows and rapid recovery signals aggressive dip-buying. Intraday 5‑minute action (thin but rising volume into the close) confirms demand above 350. A key actionable level is 338–340 as first major support; as long as price holds above 350 on closing basis, risk-reward favors maintaining or adding to long positions.
More Breaking News
- STAK Inc. Stock Dips As Volatility Spikes On Light Volume
- ASTS Tumbles On $1B Convert As Piper Sandler Targets $100
- GRAB Stock Slips As Insider Selling And Fee Scrutiny Mount
- STX Jumps As Seagate Wins Wave Of Aggressive Price Target Hikes
Recent upgrades from BofA, Jefferies, and TD Cowen with targets in the $396–$474 range reinforce a positive fundamental and sentiment backdrop, driven by Vyjuvek outperformance and a de‑risking late-stage pipeline (KB801, KB407). Versus broader Healthcare and Biotech indices, KRYS offers superior growth, profitability, and balance-sheet quality, justifying a structural premium. I see near-term resistance around $395–$400 and strong technical support at $338; a 12‑month fair value target is $420.
Quick Financial Overview
Krystal Biotech Inc. is trading in a strong uptrend, with recent weekly closes clustered in the mid-$300s and a move from $338 to $362 within days. The weekly range shows higher lows and a strong close near the top of the range, which is exactly what momentum traders want to see. Intraday, the 5‑minute data show a powerful push from the high-$330s to mid-$350s, signaling aggressive buying on the day and confirming demand into strength.
On the fundamentals, KRYS printed quarterly revenue of about $116.4M and trailing revenue of roughly $389.1M, with an exceptional gross margin near 94.2%. Profitability metrics stand out for a commercial-stage biotech: EBIT margin around 41.1% and profit margin above 50% show that Vyjuvek is scaling with high operating leverage. A price-to-sales ratio near 18.5 and a P/E around 35.1 put the stock in a premium growth bucket, which usually means the tape will be sensitive to any change in growth expectations.
Balance sheet quality is another key edge for traders watching KRYS. The company holds about $823.4M in cash and short-term investments and roughly $7.3M in long-term debt, driving a current ratio around 9.5 and very low leverage. Operating cash flow near $80.4M and free cash flow around $73.2M in the latest quarter reinforce that this is not a story burning cash to survive; it is generating cash while funding a deep pipeline. That financial cushion supports the bullish stance from BofA, Jefferies, and TD Cowen as they lift price targets on KRYS.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.